Mr. Martyn Greenacre formerly served as a director of Cephalon, Inc. and as Chairman of BMP Sunstone Corporation, a pharmaceutical company based in China which had grown to over $100 million in revenue since he joined at the formation stage in 2004 and was then sold to Sanofi-Aventis in February 2011. Mr. Greenacre also served as Chief Executive Officer and director of Delsys Pharmaceutical Corporation, a formulation and drug delivery system company; as President and Chief Executive Officer and as a director of Zynaxis Inc., a biopharmaceutical company; and as Chairman Europe, SmithKline Beecham Pharmaceutical Company. He joined SmithKline & French in 1973, where he held positions of increasing responsibility in its European organization. Mr. Greenacre serves as Chairman of Life Mist Technologies, Inc., a fire suppression equipment company, and as a director of Curis, Inc. and Neostem, Inc.
